Logo image of TELO

TELOMIR PHARMACEUTICALS INC (TELO) Stock Fundamental Analysis

USA - NASDAQ:TELO - US87975F1049 - Common Stock

1.6501 USD
+0.23 (+16.2%)
Last: 10/7/2025, 9:54:10 AM
Fundamental Rating

2

Overall TELO gets a fundamental rating of 2 out of 10. We evaluated TELO against 196 industry peers in the Pharmaceuticals industry. The financial health of TELO is average, but there are quite some concerns on its profitability. TELO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TELO has reported negative net income.
In the past year TELO has reported a negative cash flow from operations.
TELO Yearly Net Income VS EBIT VS OCF VS FCFTELO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

TELO's Return On Assets of -1945.37% is on the low side compared to the rest of the industry. TELO is outperformed by 96.94% of its industry peers.
The Return On Equity of TELO (-3353.87%) is worse than 82.14% of its industry peers.
Industry RankSector Rank
ROA -1945.37%
ROE -3353.87%
ROIC N/A
ROA(3y)-1092.11%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TELO Yearly ROA, ROE, ROICTELO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

TELO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TELO Yearly Profit, Operating, Gross MarginsTELO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for TELO has been increased compared to 1 year ago.
TELO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TELO Yearly Shares OutstandingTELO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
TELO Yearly Total Debt VS Total AssetsTELO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

Based on the Altman-Z score of -48.55, we must say that TELO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -48.55, TELO is not doing good in the industry: 89.80% of the companies in the same industry are doing better.
There is no outstanding debt for TELO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.55
ROIC/WACCN/A
WACCN/A
TELO Yearly LT Debt VS Equity VS FCFTELO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 2.38 indicates that TELO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.38, TELO is in line with its industry, outperforming 43.88% of the companies in the same industry.
TELO has a Quick Ratio of 2.38. This indicates that TELO is financially healthy and has no problem in meeting its short term obligations.
TELO's Quick ratio of 2.38 is in line compared to the rest of the industry. TELO outperforms 49.49% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
TELO Yearly Current Assets VS Current LiabilitesTELO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.59% over the past year.
EPS 1Y (TTM)39.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TELO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.63%
EPS Next 2Y21.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TELO Yearly Revenue VS EstimatesTELO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 500K 1M 1.5M
TELO Yearly EPS VS EstimatesTELO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TELO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TELO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELO Price Earnings VS Forward Price EarningsTELO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELO Per share dataTELO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as TELO's earnings are expected to grow with 21.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.72%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TELO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELOMIR PHARMACEUTICALS INC

NASDAQ:TELO (10/7/2025, 9:54:10 AM)

1.6501

+0.23 (+16.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10
Inst Owners8.75%
Inst Owner Change0%
Ins Owners16.07%
Ins Owner Change0%
Market Cap53.27M
AnalystsN/A
Price Target15.81 (858.12%)
Short Float %8.57%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-38.48%
Min EPS beat(2)-108.33%
Max EPS beat(2)31.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 110.69
P/tB 110.69
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1945.37%
ROE -3353.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1092.11%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -48.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
EPS Next Y29.63%
EPS Next 2Y21.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-122.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-186.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-186.02%
OCF growth 3YN/A
OCF growth 5YN/A